These observations prompted us to look for the effect of the KRAS mutational status in correlation with response and survival data in patients with advanced colorectal cancer receiving oxaliplatin containing chemotherapy from a prospective randomized multicenter phase III trial of the German AIO study group. The gene discussed is KRAS; the disease is colorectal cancer.